Glaxo Group Ltd

Stevenage, United Kingdom

Glaxo Group Ltd

Stevenage, United Kingdom
SEARCH FILTERS
Time filter
Source Type

Patent
Glaxo Group Ltd | Date: 2017-08-30

The present invention concerns a method of humanising antigen binding proteins and fragments. The invention particularly concerns a method of humanising antibodies, in particular those which specifically bind Oncostatin M (OSM), particularly human OSM (hOSM) and which inhibit the binding of OSM to the gp130 receptor but does not directly interact with site II residues. Further disclosed are antigen binding proteins produced by such methods pharmaceutical compositions, screening and medical treatment methods.


Patent
Glaxo Group Ltd | Date: 2017-04-12

A package (10, 20, 30, 40, 50) which can be torn open by a user, comprising a polymer film material having a preferential tearing direction and defining a cavity for a product, wherein the polymer film material incorporates a bias (16, 24, 35, 56) facilitating tearing along a tear line oriented in a direction other than its preferential tearing direction and a tear initiation location (18, 26, 37, 41, 58) which facilitates tearing of the polymer film material in its preferential tearing direction to open the package, the tear line being adjacent to a tear initiation location. The polymer film material having a preferential tearing direction provides resistance against a child tearing open the package.


Patent
Glaxo Group Ltd and DMV Fonterra Excipients Technology GmbH | Date: 2017-08-02

A process for forming lactose suitable for use in a pharmaceutical formulation comprises providing a plurality of lactose particles containing no more than 10% w/w of lactose particles having a volume average particle size of about 70 microns or less; milling the plurality of lactose particles to yield a plurality of milled lactose particles with an average particle size, (D50), ranging from about 50 microns to about 100 microns; and classifying the plurality of milled lactose particles into at least two fractions comprising a fine fraction and a coarse fraction wherein the fine fraction has an average particle size, (D50), ranging from about 3 microns to about 50 microns, and the coarse fraction has an average particle size, (D50), ranging from about 40 microns to about 250 microns.


The present invention features compounds of formula (I) and salts thereof, pharmaceutical compositions comprising said compounds and uses of such compounds in treating viral infections, such as HCV infections and diseases associated with such infections.


Patent
GLAXO GROUP Ltd | Date: 2017-02-09

The present invention concerns antigen binding proteins and fragments thereof which specifically bind Oncostatin M (OSM), particularly human OSM (hOSM) and which inhibit the binding of OSM to the gp130 receptor but does not directly interact with site II residues. The invention also concerns a method of humanising antibodies. Further disclosed are pharmaceutical compositions, screening and medical treatment methods.


Patent
GLAXO GROUP Ltd | Date: 2017-04-28

An inhalation device having at least one elongate medicament carrier including, but not limited to, a pair of sheets sealed together and a plurality of medicament powder doses positioned at spaced-apart locations between said sealed sheets, an outlet for a user to inhale from, and a mechanism for stepwise advancement of the at least one elongate medicament carrier.


Patent
Glaxo Group Ltd | Date: 2017-01-04

Muscarinic Acetylcholine Receptor Antagonists and therapeutic methods of using them are provided.


Patent
Glaxo Group Ltd | Date: 2017-02-01

A dispensing container (10) for extrudable fluid materials having a collapsible tubular body (11) with a dispensing nozzle (15) at one end (11A) and the opposite end (11B) being closed with an end wall member (20) biased to fold about a fold axis transverse to the longitudinal direction of the tubular body, wherein the end wall member either comprises a wall part of which two surfaces (81A, 81B) enclose a concave angle between them and being foldable about a fold axis in the direction of the length of the valley or the end wall member bulges convexly in a generally conical shape.


Patent
Glaxo Group Ltd | Date: 2017-02-15

The invention is directed to methods of treatment using compounds of formula (I): and salts thereof. The compounds of the invention are inhibitors of kinase activity, in particular PI3-kinase activity.


Patent
Glaxo Group Ltd | Date: 2017-09-13

The present invention provides methods of reducing the levels of a titratable selectable pressure required, the number of amplification cycles, and the time taken to generate protein expressing cell lines by altering the codons of the desired open-reading-frames. Through the use of codon adaptation for this purpose the methods of the invention consistently provide sufficient yields in faster time frames saving many weeks in cell line development activities. Furthermore the methods of the invention also generate cell lines with lower concentrations of selection and amplification agent than previously achievable. Accordingly lower levels of selection and amplification marker in the final cells lines are observed.

Loading Glaxo Group Ltd collaborators
Loading Glaxo Group Ltd collaborators